A5079416974- Childhood Cancer Survivors' Quality of Life
- Family Support in Illness
- Acute Lymphoblastic Leukemia research
- Optimism, Hope, and Well-being
- Cancer-related cognitive impairment studies
- Psychosomatic Disorders and Their Treatments
- Cancer survivorship and care
- Palliative Care and End-of-Life Issues
- Identity, Memory, and Therapy
- Adolescent and Pediatric Healthcare
- Tryptophan and brain disorders
- Asian Geopolitics and Ethnography
- Sex work and related issues
- Glioma Diagnosis and Treatment
- Stress Responses and Cortisol
- Neuroendocrine regulation and behavior
College of Mount Saint Vincent
2021-2023
St. Jude Children's Research Hospital
2015-2018
Nationwide Children's Hospital
2016
Emory University
2016
Northwestern University
2016
Fred Hutch Cancer Center
2016
Louisiana State University
2016
Fordham University
2015
Purpose In the general population, psychological symptoms frequently co-occur; however, profiles of symptom comorbidities have not been examined among adolescent survivors childhood cancer. Patients and Methods Parents 3,893 5-year cancer who were treated between 1970 1999 assessed in adolescence (age 12 to 17 years) completed Behavior Problems Index. Age- sex-standardized z scores calculated for domains by using Childhood Cancer Survivor Study sibling cohort. Latent profile analysis...
The current study was performed to examine associations between childhood cancer therapies, chronic health conditions, and symptoms of emotional distress in adult survivors cancer.Participants included 5021 (mean age, 32.0 years [standard deviation, 7.6 years] with a time since diagnosis 23.2 4.5 years]) who completed measures assessing anxiety, depression, posttraumatic stress. Cardiac, pulmonary, endocrine conditions were graded using the National Cancer Institute Common Terminology...
Abstract Objective To examine the potential mediating role of body image dissatisfaction on association between treatment‐related scarring/disfigurement and psychological distress in adult survivors childhood cancer. Methods Participants included 1714 cancer (mean [SD] age at evaluation = 32.4 [8.0] years, time since diagnosis 24.1 [8.1] years) enrolled St. Jude Lifetime Cohort Study. Survivors completed measures image, emotional distress, posttraumatic stress symptoms (PTSS). Body (BID) was...
To estimate the level of alcohol consumption behaviors in adult survivors childhood cancer and to test associations between symptoms neurocognitive impairment emotional distress.Retrospective cohort study with longitudinal follow-up self-reported health outcomes.Childhood Cancer Survivor Study (CCSS), a 26-center ≥ 5-year diagnosed ≤ 21 years age 1970 1986 United States Canada.A total 4484 [mean (standard deviation) at evaluation = 34.8 (6.1) years; time from diagnosis 24.8 (4.4) years] 1651...
The current study presents preliminary correlational data used to develop a model depicting the psychosocial pathways that lead health behaviors of survivors childhood and young-adult cancer. Data collected from sample 18- 30-year-old cancer (n = 125) was examine relations among interpersonal support nonsupport, personal agency, avoidance, depressive symptoms self-efficacy as they related behaviors. outcome measures examined included tobacco alcohol use, diet, exercise, sunscreen medication...
10570 Background: Survivors of childhood cancer who received CNS-directed therapies are at risk for neurologic sequelae, which may adversely impact psychological functioning and independence in adulthood. Methods: Participants included 7,942 survivors treated from 1970-99 with cranial radiation, intrathecal methotrexate or cytarabine (59% leukemia; 27% CNS tumor; 11% non-Hodgkin; 3% other; mean[SD] age = 25.5[5.8] yrs, time since diagnosis 17.7[4.6] yrs). Self-reported conditions stroke,...
Abstract Objective To examine associations between neurologic late effects and attainment of independence in adult survivors childhood cancer treated with central nervous system (CNS)‐directed therapies. Methods A total 7881 cranial radiation therapy ( n = 4051; CRT) and/or intrathecal methotrexate 4193; IT MTX) ([CNS‐treated]; median age [range] 25.5 years [18–48]; time since diagnosis 17.7 [6.8–30.2]) 8039 without CNS‐directed reported conditions including stroke, seizure, neurosensory...